| FUNDAMENTALS |
| MarketCap: |
0.315 mill
|
| EPS: |
0
|
| P/E: |
0
|
| Earnings Date: |
N/A |
| SharesOutstanding: |
209.90 mill
|
| Avg Daily Volume: |
0 mill
|
| RATING
2024-01-17 |
|
C+
|
|
Sell
|
| RATINGS |
| Rating CashFlow: |
Neutral
|
|
| Return On Equity: |
Strong Buy
|
|
| Return On Asset: |
Strong Sell
|
|
| DE: |
Strong Sell
|
|
| P/E: |
Sell
|
|
| Price To Book: |
Strong Sell
|
|
| QUARTER GROWTHS |
|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 |
| Revenue | | | | | | |
| Gr.Profit | | | | | | |
| Ebit | | | | | | |
| Asset | | | | | | |
| Debt | | | | | | |
| PE RATIO: COMPANY / SECTOR |
|
0.00x
|
|
Company: PE 0 | sector: PE -11.58
|
| PE RATIO: COMPANY / INDUSTRY |
|
N/A
|
|
Company: PE 0 | industry: PE -107.25
|
| DISCOUNTED CASH FLOW VALUE |
|
N/A
|
|
N/A
|
| Expected Trading Range (DAY) |
$ 0.0005 - 0.0025
( +/- 66.67%)
|
|
ATR Model: 14 days
|
Insider Trading
| Date |
Person |
Action |
Amount |
type |
| 2022-06-30 | Striepe Thomas | Sell | 0 | Common Stock |
| 2022-06-30 | Schmelz Hubertus | Sell | 0 | Common Stock |
| 2021-10-13 | Schmelz Hubertus | Buy | 1 200 000 | Common Stock |
| 2021-06-30 | Schmelz Hubertus | Sell | 0 | Common Stock |
| 2021-06-30 | Striepe Thomas | Sell | 0 | Common Stock |
| INSIDER POWER |
|
0.00
|
| Last
82 transactions |
| Buy:
3 836 313 | Sell:
156 955 |
Forecast:
01:40 - $-0.0010
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
| Indicator Signals |
| RSI 21 |
|
| SMA |
|
| Trend |
|
| Trend 2 |
|
| Trend 3 |
|
| MACD |
|
| Volume Signals |
| Price |
$0.0015 (0.00% )
|
| Volume |
0.200 mill
|
| Avg. Vol. |
0 mill
|
| % of Avg. Vol |
0 %
|
| Signal 1: |
|
| Signal 2: |
|
Last 10 Buy & Sell Signals For SGBI
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Sangui Biotech International, Inc., through its subsidiary, Sangui BioTech GmbH, develops hemoglobin-based artificial oxygen carriers for use as blood additives, blood volume substitutes, and variant products. The company's artificial oxygen carriers provide oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia, or blood loss, as well as chronic wounds. It also offers nano formulations for the regeneration of skin, including skin moisturization and enhanced skin elasticity; Chitoskin wound pads for supporting wound healing; and Hemospray wound spray, a medical product that is used for the healing of chronic wounds. The company sells its wound spray products under the Granulox brand name primarily in Europe and Mexico; and cosmetics products through internet shop. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany.
The Technical Analyst
